Nuwellis (NUWE) Peer Comparison

$0.97

$-0.02 (-2.29%)

As on 28-Aug-2026 13:36EDT

Market cap

$4 Mln

Revenue (TTM)

$9 Mln

P/E Ratio

0

P/B Ratio

0.2

Div. Yield

0 %

Edit

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	4	12,753	10,906	10,222	9,762
Revenue ($ Mln)	9	1,505	613	785	2,589
Net Profit ($ Mln)	-11.12	160.59	-188.05	41.54	222.40
Net Margin (%)	-123.38	10.67	-30.68	5.29	8.59
RoE (%)	--	10.86	-28.10	1.97	3.04
Price to Earnings	0.00	79.35	--	251.57	44.47
Price-To-Book	0.18	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	9.01	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	2.73	483.98	127.96	384.30	1,245.50
Gross Profit	5.12	942.44	393.22	347.62	1,343.60
Operating Expenses	18.96	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-12.67	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-11.12	203.83	-192.83	52.15	350.40
Provision for Tax	0.00	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-11.12	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	-2.06	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	7.16	210.18	135.71	705.49	2,116.80
Current Liabilities	4.01	233.78	102.33	132.66	961.30
Total Liabilities	6.12	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	1.23	630.60	404.74	1,749.63	7,231.50
Current Assets	7.90	1,344.12	515.78	1,200.55	3,020.50
Total Assets	6.11	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	0.20	212.71	102.84	690.94	1,203.70
Net Current Assets	0.00	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-10.81	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-0.09	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	6.94	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-349.48	11.76	-22.53	1.79	8.98
ROE (%)	-382.81	10.86	-28.10	1.97	3.04
ROA (%)	-73.85	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-69.81	13.63	-30.58	9.87	-5.99
Net Margin (%)	-123.38	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	8.36	17.55	41.55	16.49	1.37
EBIT Growth (%)	-28.72	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	24.24	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-333.36	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	73.94	17.33	-12.65	2.16	2.19

Valuation Ratios

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	0.00	68.93	-34.59	189.42	--
Price / Book Value	0.03	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	0.10	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	-0.10	0.01	0.00	0.01	0.06
Current Ratio	1.97	5.75	5.04	9.05	3.14
Quick Ratio	1.54	3.86	4.46	7.64	2.33
Interest Coverage	-0.66	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Nuwellis (NUWE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	17.14	12.65	22.67	20.09	17.06
Asset Turnover	0.60	0.74	0.59	0.26	0.24
Receivable days	71.11	46.54	60.95	72.41	65.39
Inventory Days	210.61	331.92	193.84	146.53	221.09
Payable days	210.14	26.16	60.19	29.05	37.02
Cash Conversion Cycle	71.57	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly